- Home
- BRIA vs ARMP Comparison
BRIA vs ARMP Comparison
Compare BRIA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- ARMP
- Stock Information
- Founded
- BRIA 2011
- ARMP N/A
- Country
- BRIA Singapore
- ARMP United States
- Employees
- BRIA N/A
- ARMP N/A
- Industry
- BRIA
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRIA
- ARMP Health Care
- Exchange
- BRIA NYSE
- ARMP Nasdaq
- Market Cap
- BRIA 47.1M
- ARMP 52.1M
- IPO Year
- BRIA 2024
- ARMP N/A
- Fundamental
- Price
- BRIA $2.47
- ARMP $1.91
- Analyst Decision
- BRIA
- ARMP Strong Buy
- Analyst Count
- BRIA 0
- ARMP 1
- Target Price
- BRIA N/A
- ARMP $9.00
- AVG Volume (30 Days)
- BRIA 8.7K
- ARMP 36.4K
- Earning Date
- BRIA 08-15-2025
- ARMP 08-12-2025
- Dividend Yield
- BRIA N/A
- ARMP N/A
- EPS Growth
- BRIA N/A
- ARMP N/A
- EPS
- BRIA 92.24
- ARMP N/A
- Revenue
- BRIA $59,695,825.00
- ARMP $4,699,000.00
- Revenue This Year
- BRIA N/A
- ARMP $8.43
- Revenue Next Year
- BRIA N/A
- ARMP N/A
- P/E Ratio
- BRIA $0.03
- ARMP N/A
- Revenue Growth
- BRIA 8.03
- ARMP 14.24
- 52 Week Low
- BRIA $1.78
- ARMP $0.90
- 52 Week High
- BRIA $4.38
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- ARMP 52.83
- Support Level
- BRIA N/A
- ARMP $1.74
- Resistance Level
- BRIA N/A
- ARMP $2.00
- Average True Range (ATR)
- BRIA 0.00
- ARMP 0.15
- MACD
- BRIA 0.00
- ARMP -0.03
- Stochastic Oscillator
- BRIA 0.00
- ARMP 43.59
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.